Skip to content

LOCKERMAN FINANCIAL GROUP, INC.: CME position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of LOCKERMAN FINANCIAL GROUP, INC. on CME, newest first. How the timeline and the estimate are built.

LOCKERMAN FINANCIAL GROUP, INC. held 0 CME shares at 2025-09-30 per its 13F-HR filed 2025-10-16.

the latest 13F is the newest step

  1. period ended2025-09-30
    13F 0 shares
    Change vs previous 13F -949 shares

    13F-HR 0001906539-25-000002 filed by LOCKERMAN FINANCIAL GROUP, INC.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  2. period ended2025-06-30
    13F 949 shares
    Change vs previous 13F -3 shares

    0.35% of the 13F portfolio, value $261,564.

    13F-HR 0001085146-25-003960 filed by LOCKERMAN FINANCIAL GROUP, INC.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-03-31
    13F 952 shares
    Change vs previous 13F -6 shares

    0.38% of the 13F portfolio, value $252,557.

    13F-HR 0001085146-25-002162 filed by LOCKERMAN FINANCIAL GROUP, INC.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2024-12-31
    13F 958 shares
    Change vs previous 13F -1 shares

    0.38% of the 13F portfolio, value $222,477.

    13F-HR 0001085146-25-000301 filed by LOCKERMAN FINANCIAL GROUP, INC.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2024-09-30
    13F 959 shares
    Change vs previous 13F not available

    0.36% of the 13F portfolio, value $211,604.

    13F-HR 0001085146-24-004910 filed by LOCKERMAN FINANCIAL GROUP, INC.
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).